Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Journal of Environmental Pathology, Toxicology and Oncology
IF: 1.241 5-Year IF: 1.349 SJR: 0.519 SNIP: 0.613 CiteScore™: 1.61

ISSN Print: 0731-8898
ISSN Online: 2162-6537

Journal of Environmental Pathology, Toxicology and Oncology

DOI: 10.1615/JEnvironPatholToxicolOncol.2018027447
pages 305-316

Potential Role of Induced Pluripotent Stem Cells as Regenerative Medicine in Retinal Cell Damage

Ying-Jian Sun
Department of Ophthalmology, The Second Hospital of Jilin University, Changchun, Jilin 130041, China
Yi-Ran Pan
Department of Ophthalmology, The Second Hospital of Jilin University, Changchun, Jilin 130041, China
Bin Fan
Department of Ophthalmology, The Second Hospital of Jilin University, Changchun, Jilin 130041, China
Guang-Yu Li
Department of Ophthalmology, The Second Hospital of Jilin University, Changchun, Jilin 130041, China

ABSTRACT

Induced pluripotent stem cells (also called iPSCs) are somatic cells reprogrammed by overexpressing four nuclear transcriptional factors containing Sox2, Klf4, c-myc and Oct4 is the one of research hotspots. Its pluripotency, self-renewal capacity and wide accessibility to donor tissues have made possible the means for modified regenerative medicine. They are considered a possible basis of healthy tissue to cure diseases, like ophthalmic diseases, degenerative diseases, age-related macular degeneration (AMD), are primarily because of the weakening capability of photoreceptor cells, retinal ganglion cells (RGCs), retinal pigmented epithelium (RPE) or other retinal cells. And these retinal cells are unable to regenerate and currently there are no effective treatments to restore sight. iPSCs allow for the in vitro development of numerous varieties of retinal cells, and may treat these diseases by retinal transplantation. Although other stem cells could differentiate into retinal cells, iPSCs derived retinal cells might have numerous benefits as compared to other stem cell sources including embryonic stem (ES) cells. Mainly they would be directly obtained from the patient, therefore eradicating every probable chance of adverse immune responses. Second, making iPSCs just needs somatic cells, thus circumventing the valid ethical issues which limited the clinic use of ES cells derived from human. Third, iPSCs are parallel to ES cells in differentiation ability, they can be expanded in vitro and induced to differentiate into retinal cells, providing a renewable source for therapeutic applications and scientific researches. In this current review, we have concise latest progresses


Articles with similar content:

Tissues Reborn: Fetal Membrane-Derived Matrices and Stem Cells in Orthopedic Regenerative Medicine
Critical Reviews™ in Biomedical Engineering, Vol.42, 2014, issue 3-4
Natasha Topoluk, Jeremy Mercuri, Renae Keeley
Retinal Pigment Epithelium Differentiation of Stem Cells: Current Status and Challenges
Critical Reviews™ in Biomedical Engineering, Vol.37, 2009, issue 4-5
Martin Yarmush, Basak E. Uygun, Nripen Sharma
Schizophrenia and Glutamatergic Transmission
Critical Reviews™ in Neurobiology, Vol.12, 1998, issue 1-2
Carol A. Tamminga
Dental Tissue−Derived Mesenchymal Stem Cells: Applications in Tissue Engineering
Critical Reviews™ in Biomedical Engineering, Vol.46, 2018, issue 5
Jay R. Dave, Geetanjali B. Tomar
Notochordal Cells in the Adult Intervertebral Disc: New Perspective on an Old Question
Critical Reviews™ in Eukaryotic Gene Expression, Vol.21, 2011, issue 1
Makarand V. Risbud, Irving M. Shapiro